MASH is marked by inflammation and fibrosis and can progress ... whose clinical focus is on metabolic-associated steatotic ...

Results support potential benefit of efruxifermin (EFX) to elicit fibrosis improvement in patients with compensated cirrhosis ...

According to a new major clinical trial known as the ESSENCE trial, semaglutide—better known as Ozempic when used for Type 2 ...

Results support potential benefit of efruxifermin (EFX) to elicit fibrosis improvement in patients with compensated cirrhosis (F4 fibrosis) due to MASH 96-week data from SYMMETRY trial presented at EA ...

More patients in the linerixibat group had clinically meaningful itch improvement (WI-NRS =3-point reduction) with 56% versus 43% in the placebo group at week 24 (treatment difference 13% [95% CI ...

We recently published an article titled Billionaire Nicholas J. Pritzker’s 8 Stocks with Huge Upside Potential. In this ...

An experimental new treatment is showing early promise in the fight against liver fibrosis—a serious and often silent condition that affects around 2 million people in the UK.

Biomedical research in liver diseases has traditionally depended on animal models, but ethical concerns and the quest for ...

Axiomer ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Strengthened ...

LONDON, UK / ACCESS Newswire / May 9, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), is pleased to announce that it has raised gross proceeds of £500,000 (before ...

We expected miracles; what we got was a legal minefield. As GLP-1 drugs like Ozempic reshape bodies and bottom lines, a ...